

Florent Mouliere

List of Publications by Citations

Source: <https://exaly.com/author-pdf/977712/florent-mouliere-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

42
papers

4,201
citations

20
h-index

58
g-index

58
ext. papers

5,368
ext. citations

9.3
avg, IF

5.46
L-index

#	Paper	IF	Citations
42	Liquid biopsies come of age: towards implementation of circulating tumour DNA. <i>Nature Reviews Cancer</i> , 2017 , 17, 223-238	31.3	1192
41	Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. <i>Nature Medicine</i> , 2014 , 20, 430-5	50.5	474
40	Circulating cell free DNA: Preanalytical considerations. <i>Clinica Chimica Acta</i> , 2013 , 424, 222-30	6.2	365
39	Enhanced detection of circulating tumor DNA by fragment size analysis. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	350
38	High fragmentation characterizes tumour-derived circulating DNA. <i>PLoS ONE</i> , 2011 , 6, e23418	3.7	337
37	Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. <i>Neurobiology of Disease</i> , 2008 , 31, 316-26	7.5	232
36	Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. <i>Nucleic Acids Research</i> , 2010 , 38, 6159-75	20.1	207
35	Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. <i>Molecular Oncology</i> , 2014 , 8, 927-41	7.9	145
34	Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. <i>Translational Oncology</i> , 2013 , 6, 319-28	4.9	125
33	Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care. <i>Clinical Cancer Research</i> , 2016 , 22, 3067-77	12.9	110
32	Circulating tumor-derived DNA is shorter than somatic DNA in plasma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 3178-9	11.5	98
31	Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA. <i>Cancer Cell</i> , 2019 , 36, 350-368	24.3	90
30	Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	71
29	The value of cell-free DNA for molecular pathology. <i>Journal of Pathology</i> , 2018 , 244, 616-627	9.4	62
28	The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12 Suppl 1, S209-15	5.4	58
27	ctDNA monitoring using patient-specific sequencing and integration of variant reads. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	57
26	Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer. <i>Scientific Reports</i> , 2017 , 7, 5554	4.9	51

25	Measurement of Plasma Cell-Free Mitochondrial Tumor DNA Improves Detection of Glioblastoma in Patient-Derived Orthotopic Xenograft Models. <i>Cancer Research</i> , 2019 , 79, 220-230	10.1	44
24	Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. <i>Genome Medicine</i> , 2020 , 12, 23	14.4	37
23	A phylogenetic latent feature model for clonal deconvolution. <i>Annals of Applied Statistics</i> , 2016 , 10,	2.1	31
22	Fragmentation patterns and personalized sequencing of cell-free DNA in urine and plasma of glioma patients. <i>EMBO Molecular Medicine</i> , 2021 , 13, e12881	12	15
21	Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors. <i>Oncotarget</i> , 2018 , 9, 32570-32579	3.3	12
20	Selecting short DNA fragments in plasma improves detection of circulating tumour DNA		8
19	Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients - initial observations. <i>PLoS ONE</i> , 2020 , 15, e0231884	3.7	5
18	Cell-Free DNA Fragmentomics: The New "Omics" on the Block. <i>Clinical Chemistry</i> , 2020 , 66, 1480-1484	5.5	4
17	High-sensitivity monitoring of ctDNA by patient-specific sequencing panels and integration of variant reads		4
16	Circulating DNA analysis and concordance with tumor section analysis in the detection of KRAS and BRAF point mutations from metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10505-10505	2.2	3
15	Personalized Medicine by Analyzing Circulating DNA: Application to the Management Care of Colorectal Cancer Patients. <i>Annals of Oncology</i> , 2013 , 24, i7	10.3	2
14	Refined characterization of circulating tumor DNA through biological feature integration.. <i>Scientific Reports</i> , 2022 , 12, 1928	4.9	2
13	Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA.. <i>Genome Research</i> , 2021 ,	9.7	2
12	Detection of Genetic Alterations by Nucleic Acid Analysis: Use of PCR and Mass Spectroscopy-Based Methods. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2015 , 89-111	10.4	1
11	P3.12 Circulating Dna Analysis in The Era of Personalized Cancer Medicine: Application to Kras/Braf Point Mutations Detection in Colorectal Cancer. <i>Annals of Oncology</i> , 2012 , 23, v36-v37	10.3	1
10	Integrated clonal analysis reveals circulating tumor DNA in urine and plasma of glioma patients		1
9	PCR-Free Shallow Whole Genome Sequencing for Chromosomal Copy Number Detection from Plasma of Cancer Patients Is an Efficient Alternative to the Conventional PCR-Based Approach. <i>Journal of Molecular Diagnostics</i> , 2021 , 23, 1553-1563	5.1	0
8	Circulating DNA as a strong multimarker prognostic tool in metastatic colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3604-3604	2.2	

- 7 CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number changes.. *Journal of Clinical Oncology*, **2016**, 34, 11530-11530 2.2
- 6 A pilot study of individualised monitoring of patients with metastatic melanoma using plasma and urine DNA.. *Journal of Clinical Oncology*, **2017**, 35, e21032-e21032 2.2
- 5 Circulating tumor DNA (ctDNA) analysis by low-coverage whole genome sequencing (lcWGS) of resectable esophageal adenocarcinoma (rEAC) patients.. *Journal of Clinical Oncology*, **2021**, 39, 4033-4033²
- 4 Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients Initial observations **2020**, 15, e0231884
- 3 Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients Initial observations **2020**, 15, e0231884
- 2 Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients Initial observations **2020**, 15, e0231884
- 1 Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients Initial observations **2020**, 15, e0231884